Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

The Action Mechanism of Tamoxifen Via Estrogen Receptor on Uterine Leimyoma

자궁근종에서 타목시펜의 수용체를 통한 기전

  • Lee, Byung-Seok (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Cha, Dong-Hyun (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Jung, Kyung-Ah (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Lee, Hye-Dae (Department of Obstetrics & Gynecology, Breast Cancer Center, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Park, Ki-Hyun (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Cho, Dong-Jae (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University) ;
  • Song, Chan-Ho (Department of Obstetrics & Gynecology, YongDong Severance Hospital, College of Medicine, Yonsei University)
  • 이병석 (연세대학교 의과대학 영동세브란스병원 산부인과학교실) ;
  • 차동현 (연세대학교 의과대학 영동세브란스병원 산부인과학교실) ;
  • 정경아 (연세대학교 의과대학 영동세브란스병원 산부인과학교실) ;
  • 이희대 (연세대학교 의과대학 영동세브란스병원 산부인과학교실 유방암센터) ;
  • 박기현 (연세대학교 의과대학 영동세브란스병원 산부인과학교실) ;
  • 조동제 (연세대학교 의과대학 영동세브란스병원 산부인과학교실) ;
  • 송찬호 (연세대학교 의과대학 영동세브란스병원 산부인과학교실)
  • Published : 2002.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To investigate the distribution of $ER{\alpha}$, $ER{\beta}$, c-fos and c-jun in the uterine myoma and myometrium in oder to know how the tamoxifen cause the growth of myoma. Methods: Myoma and myometrial tissue were obtained from the postmenopausal women treated with tamoxifen in the patients with breast cancer and in the premenopausal patients, who were undergoing myoma of uterus from 1998 through 2000. The espression of each gene was quantitated with quantitative RT-PCR. Results: The expression of $ER{\alpha}$ was slightly increased in the myoma than the myometrium in the proliferative phase, and was slightly decreased in the myometrium than the myoma in the secretory phase. However it was not significant statistically. In the postmemopausal women treated with tamoxifen, $ER{\alpha}$ was expressed in all myoma and myome1rial tissues and the expression was not statistically significant. The expression ofER~ was slightly increased in the myome1rium than the leiomyoma in the proliferative and secretory phase, but it was not significant statistically. In the postmemopausal women treated with tamoxifen, the expression of ER~ was significantly incresed in the myome1rium than the leiomyoma. The expression of c-fos was significantly increased in the myome1rium than the leiomyoma in the proliferative and secretory phase. In the postmemopausal women treated with tamoxifen, the expression of c-fos was slightly increased in the leiomyoma than the myomelrium, however, it was not statistically significant. Conclusion: Tamoxifen may cause the growth of leiomyoma by $ER{\alpha}$ with AP-l pathway reducing the counteraction of 6$ER{\beta}$ to $ER{\alpha}$.

Keywords

References

  1. Mosselman S, Polman J, Dijkema R. ER$\beta$: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53 https://doi.org/10.1016/0014-5793(96)00782-X
  2. Berry M, Metzger D, Chambon P. Role of the activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9: 2811-8
  3. Tzuckerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally disticnt intramolecular regions. Mol Endocrinol 1994; 8: 21-30 https://doi.org/10.1210/me.8.1.21
  4. Jordan VC, Morrow M. Should Clinicians be concerned about the carcinogenic potential of tamoxifen? EurJ Cancer1994; 11: 1714-21
  5. Friedl A, Jordan VC. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994; 31: 27-39 https://doi.org/10.1007/BF00689674
  6. Fisher DA, Lakshmanan J Metabolism and effects of epidermal growth factor and their reated grawth factors in mammals. Endocr Rev 1990;11: 418
  7. Lippman ME, Dickson RB, Knabbe C, et al, Autocrine and paracrine growth regulation of breast cancer. Breast Cancer Res Treat 1986;7: 59
  8. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-$\beta$3 (TGF$\beta$3) and altered responses to the antiproliferative effects of TGF$\beta$. J Clin Endocrinology & Metabolism 2001; 86(2): 913-20 https://doi.org/10.1210/jc.86.2.913
  9. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochem Biophys Acta 1991; 1072: 129-57
  10. Green S, Chambon P. The oestrogen receptor: From perception to mechanism, in Parker M(ed):Nuclear hormone receptors. London, UK, Academic Press 1991; 15-38
  11. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid hormone family: Structure and function. Endocr Rev 1990; 11: 201-20 https://doi.org/10.1210/edrv-11-2-201
  12. Callo MA, Kaufman D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 1997; 24: S171-S180
  13. Astruc ME, Chabret C, Bali P, Gagne D, Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the AP-1 mediated response: Involvement of the estrogen receptor. Endocrinology 1995; 136: 824-32 https://doi.org/10.1210/en.136.3.824
  14. Webb P, Lopez GN, Uht RM, Kushner PJ Tamoxifen activation of the estrogen receptor/AP-1 path way: Potential origen for the cell-specific estrogenlike effects of antiestrogens. Mol Endocrinol 1995; 9: 443-56
  15. Pellerin I, Vuillermoz C, Jouvenot M, Royez M, Ordener C, Marechal G, Adessi G. Superinduction of c-Fos gene expression by estrogen in cultured guinea-pig endometrial cells requires priming by a cycloheximide-dependent mechanism. Endocrinology 1992; 131: 1094-100 https://doi.org/10.1210/en.131.3.1094
  16. Nephew KP, Polek TC, Khan SA. Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium. Endocrinology 1996; 137: 219-24 https://doi.org/10.1210/en.137.1.219
  17. Hall JM, McDonnell DP. The estrogen receptor $\beta$-isoform (ER$\beta$) of the human estrogen receptor modulaes ER$\alpha$ transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78 https://doi.org/10.1210/en.140.12.5566
  18. Saez E, Rutberg SE, Mueller E, et al. c-fos is required for malignant progression of skin tumors. Cell 1995; 82: 721-32 https://doi.org/10.1016/0092-8674(95)90469-7